Circumvention of acquired resistance to topoisomerase II-targeted anticancer agents in HL-60 leukemia cells by prevention of intronic polyadenylation [0.03%]
通过防止内含子多腺苷酸化来克服HL-60白血病细胞中拓扑异构酶II靶向抗癌剂获得性耐药性的策略
Xinyu Zhao,Sydney R Cassel,Sarah E Eaton et al.
Xinyu Zhao et al.
DNA topoisomerase IIα (TOP2α; 170 kDa, TOP2α/170) is a nuclear enzyme that plays a key role in chromosomal segregation at mitosis by catalyzing transient DNA double-stranded breaks, allowing replicated DNA duplexes to separate. Given its...
Lumateperone as an alternative to clozapine in treatment-resistant schizophrenia: Insights from a quantitative systems pharmacology model [0.03%]
定量系统药理学模型中有关Lumateperone作为难治性精神分裂症治疗方法的研究
Archana Mishra,Biswa Ranjan Mishra,Rituparna Maiti et al.
Archana Mishra et al.
Clozapine remains the only drug with superior efficacy in treatment-resistant schizophrenia (TRS) but is limited by underutilization and significant adverse effects, motivating mechanistic approaches to identify clozapine-like alternatives....
Positive allosteric modulation of the delta opioid receptor attenuates depression-like and pain-like behaviors but does not promote convulsions [0.03%]
δ型阿片受体正别构调节抑制抑郁样和疼痛样行为但不诱发惊厥
Emily M Jutkiewicz,Benjamin A Palleiko,Isaac J Dripps et al.
Emily M Jutkiewicz et al.
The delta opioid receptor (DOR) has been a focus of research for the treatment of depression and certain pain disorders. Unfortunately, clinical translation of delta opioid agonists to humans has proved challenging partly because of their p...
The intelectin 1-bestrophin-2-glutamate axis regulates glutamate homeostasis and suppresses colorectal cancer progression [0.03%]
intelectin 1- bestrophin 2-谷氨酸轴调节谷氨酸稳态并抑制结直肠癌进展
Di Lu,Yang Zhou,Han Zhang et al.
Di Lu et al.
Colorectal cancer (CRC) is a highly prevalent malignancy with a poor prognosis, and metabolic reprogramming (eg, glutamic acid metabolism) drives its progression. However, the key regulators of glutamic acid homeostasis in CRC remain undefi...
Exosomal miR-376c-3p derived from cardiac fibroblasts triggers cardiac hypertrophy by targeting ERP44 [0.03%]
心房纤维化细胞衍生的外泌体miR-376c-3p通过靶向ERP44诱导心肌肥厚
Yuexin Zhang,Xiaopei Hu,Jie Li et al.
Yuexin Zhang et al.
Recent studies have revealed that exosomes, important regulators of intercellular communication, participate in various cardiac abnormalities, including hypertrophy. Cardiac fibroblasts (CFs) are one of the most abundant cell types of the h...
Pharmacology and nonclinical development of teplizumab, a first-in-class immunotherapy for delaying the onset of type 1 diabetes [0.03%]
特普利单抗的药理学和非临床开发研究——第一种用于延缓I型糖尿病发病的免疫疗法
Rao N V S Mamidi,Mark Peakman,Wolfgang Schmider et al.
Rao N V S Mamidi et al.
Teplizumab is a nonmitogenic anti-CD3 monoclonal antibody approved to delay the onset of clinical type 1 diabetes. To address the challenge of the absence of crossreactivity of teplizumab with CD3 of different preclinical species that are t...
Artesunate does not prevent cardiac hypertrophy but inhibits heart failure progression in mice [0.03%]
艺术酸盐不能预防心脏肥大但可抑制小鼠心力衰竭进展
Anna Zhang,Guoling Yang,Guojun Chu et al.
Anna Zhang et al.
Heart failure (HF) poses a substantial challenge to healthcare systems globally, particularly at the advanced stages of various cardiac diseases, due to its high morbidity and mortality rates. This study aimed to assess the therapeutic pote...
Low-density lipoprotein receptor-related protein 1 as a therapeutic target in acute myocardial infarction: From mechanisms to clinical translation [0.03%]
低密度脂蛋白受体相关蛋白1在急性心肌梗死治疗中的作用:从机制到临床应用
Michele Marchetta,Rocio I Lopez,Nicola Potere et al.
Michele Marchetta et al.
Low-density lipoprotein receptor-related protein-1 (LRP1) is a ubiquitously expressed, multifunctional membrane receptor that combines scavenger and signaling functions regulating, among others, lipid metabolism, inflammation and fibrosis p...
Nonclinical characterization of ACP-204, a novel selective serotonin receptor subtype 2A receptor inverse agonist [0.03%]
一种新型选择性血清素2A受体反向激动剂ACP-204的非临床特征研究
Ethan S Burstein,Roger Olsson,Niklas Skold et al.
Ethan S Burstein et al.
Pimavanserin was the first US Food and Drug Administration approved antipsychotic drug that does not block D2 dopamine receptors at therapeutic doses. Pimavanserin is a selective 5-HT2A receptor inverse agonist that reduces the frequency of...